4-N-戊(烷)基苯磺酰基氯 | 73948-18-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-N-戊(烷)基苯磺酰基氯
• 中文别名: 4-正戊基苯磺氯；对正戊基苯磺酰氯；4-正戊基苯磺酰氯;；4-正戊基苯磺酰氯
• 英文名称: 4-n-pentylbenzenesulfonyl chloride
• 英文别名: 4-pentylbenzenesulfonyl chloride；4-pentylphenylsulfonyl chloride；4-Pentylbenzene-1-sulfonyl chloride
• CAS: 73948-18-2
• 化学式: C₁₁H₁₅ClO₂S
• 分子量: 246.758
• InChiKey: XDWXZRVWJHEWMT-UHFFFAOYSA-N

物化性质

• 熔点：
  <30°C
• 沸点：
  163 °C(Press: 6.4 Torr)
• 密度：
  1.183±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  42.5
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险等级：
  8
• 危险品标志：
  C
• 危险类别码：
  R34
• 危险品运输编号：
  3265
• 海关编码：
  2904909090
• 包装等级：
  II
• 危险类别：
  8
• 安全说明：
  S26,S36/37/39,S45
• 储存条件：
  存储条件：2-8°C，密封于干燥处。

SDS

Name:	4-Pentylbenzene-1-sulfonyl chloride 97% Material Safety Data Sheet
Synonym:
CAS:	73948-18-2

Section 1 - Chemical Product MSDS Name:4-Pentylbenzene-1-sulfonyl chloride 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
73948-18-2	4-Pentylbenzene-1-sulfonyl chloride	97%	unlisted

Hazard Symbols: C
Risk Phrases: 34

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Causes burns.Moisture sensitive.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Causes skin burns.
Ingestion:
Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Do not induce vomiting. Get medical aid immediately.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Use only in a chemical fume hood.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Corrosives area. Store under nitrogen.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 73948-18-2: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: < 30 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C11H15ClO2S
Molecular Weight: 247

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials, exposure to moist air or water.
Incompatibilities with Other Materials:
Strong oxidizing agents, bases.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, carbon monoxide, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 73948-18-2 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-Pentylbenzene-1-sulfonyl chloride - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.*
Hazard Class: 8
UN Number: 3261
Packing Group: III
IMO
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3261
Packing Group: III
RID/ADR
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3261
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 34 Causes burns.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 73948-18-2: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 73948-18-2 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 73948-18-2 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-N-戊(烷)基苯磺酰基氯 在 4-二甲氨基吡啶 、 氯化亚砜 、 三乙胺 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 28.0h， 生成 methyl (2R,4R)-4-hydroxy-1-(4-pentylphenyl)sulfonylpyrrolidine-2-carboxylate
  参考文献：
  名称：

  衍生自功能化的4-氨基脯氨酸的新型异羟肟酸酯基质金属蛋白酶抑制剂的开发。

  摘要：

  从氨基脯氨酸支架制备了一系列异羟肟酸酯，并测试了其作为基质金属蛋白酶（MMP）抑制剂的功效。据报道该系列的详细SAR是针对MMP家族中的5种酶，许多抑制剂（例如化合物47）具有广谱活性，某些酶具有亚纳摩尔的效力。分子P1'部分的修饰在影响MMP家族内的效能和选择性方面起着关键作用。如化合物48-50所示，在分子的该区域中的长链脂族取代基倾向于增加对MMP-3的效力而降低对MMP-1的效力，而如化合物52中的芳族取代基产生广谱抑制作用。该数据基于X射线晶体数据也被合理化。虽然体外经口吸收似乎不太可预测，但随着更长和更多亲水性取代基的出现，吸收率往往会降低。最后，使用骨关节炎的大鼠模型评估这些化合物的功效，并在它们的药代动力学和体内功效之间建立了直接联系。

  DOI：

  10.1021/jm000246e
• 作为产物：
  描述：

  戊基苯 在 氯磺酸 作用下， 以 氯仿 为溶剂， 以85.5 %的产率得到4-N-戊(烷)基苯磺酰基氯
  参考文献：
  名称：

  不同的结构 - 相似的效果：取代的 5-(4-甲氧基苯基)-1H-吲哚和 5-(4-甲氧基苯基)-1H-咪唑是否代表底物选择性抑制 ALOX15 亚油酸加氧酶活性的常见药效团？

  摘要：

  哺乳动物 15-脂氧合酶 (ALOX15) 是脂质过氧化酶，在不同的癌症和炎症模型中表现出不同的功能。亚油酸和花生四烯酸衍生的 ALOX15 代谢物的病理生理作用使该酶成为药理学研究的目标。几种吲哚和咪唑衍生物以底物特异性方式抑制兔 ALOX15 的催化活性，但这种变构抑制的分子基础仍不清楚。在这里，我们试图定义一个共同的药效团，这对于这种变构抑制至关重要。我们发现，与吲哚衍生物相比，取代的咪唑类化合物的抑制作用较弱。使用二聚变构酶模型进行的计算机对接研究和分子动力学模拟表明，其中抑制剂占据一个单体的底物结合口袋，而底物脂肪酸结合在 ALOX15 二聚体内另一个单体的催化中心。核心药效基团的化学修饰改变了酶与抑制剂的相互作用，导致抑制效力降低。在我们的二聚 ALOX15 模型中，抑制剂结合引起的结构差异转化为疏水二聚簇，并影响酶-底物复合物的结构。这些数据特别重要，因为底物特异性抑制可能有助于阐明源自不同多不饱和脂肪酸的

  DOI：

  10.3390/molecules28145418

文献信息

• Metathesis Cascade‐Triggered Depolymerization of Enyne Self‐Immolative Polymers**
  作者：Jingsong Yuan、Gavin J. Giardino、Jia Niu

  DOI：10.1002/anie.202108239

  日期：2021.11.15

  of enyne self-immolative polymers (SIPs) capable of metathesis cascade-triggered depolymerization is reported. Studies on model compounds established 1,6-enyne structures for efficient metathesis cascade reactions. SIPs incorporating the optimized 1,6-enyne motif were prepared via both polycondensation and iterative exponential growth approaches. These SIPs demonstrated excellent stability in strong

  报道了一类能够进行复分解级联触发解聚的新型烯炔自燃聚合物 (SIPs)。对模型化合物的研究建立了用于高效复分解级联反应的 1,6-烯炔结构。通过缩聚和迭代指数增长方法制备了包含优化的 1,6-烯炔基序的 SIP。这些 SIP 在强酸、强碱、亲核试剂或高温下表现出优异的稳定性，并且一旦被复分解催化剂触发，就可以进行有效和完全的解聚。进一步的研究表明，在烯炔 SIPs 的链端引入末端烯烃提高了解聚效率，并确立了它们作为刺激响应材料的潜力。
• Sulfonylguanidine Derivatives as Potential Antimelanoma Agents
  作者：Tom Baladi、Nedra Hamouda‐Tekaya、Leticia Christina Pires Gonçalves、Stéphane Rocchi、Cyril Ronco、Rachid Benhida

  DOI：10.1002/cmdc.202000218

  日期：2020.7.3

  Sulfonylguanidines are interesting bioactive compounds with a broad range of applications in the treatment of different pathologies. 2‐Aminobenzazole‐based structures are well employed in the development of new anticancer drugs. Two series of novel N‐benzazol‐2‐yl‐N′‐sulfonyl guanidine derivatives were synthesized with the sulfonylguanidine in either an extra‐ or intracyclic frame. They were evaluated for their antiproliferative

  磺酰胍是令人感兴趣的生物活性化合物，在治疗不同病理方面具有广泛的应用。基于2-氨基苯并唑的结构在开发新的抗癌药物中得到了很好的利用。两个新的N-苯并唑-2-基-N'系列磺酰基胍衍生物是在环外或环内构架与磺酰基胍合成的。评估了它们对恶性黑色素瘤肿瘤细胞的抗增殖活性，从而确定了结构-活性关系。此外，对最佳类似物进行了NCI-60筛选，以研究其对其他癌细胞系的功效。然后验证了该有前途的化合物的稳定性。在合成过程中，还发现了磺酰胍对磺酰胺功能的意外新的脱酰胺基作用。
• Acyclic triaryl olefins possessing a sulfohydroxamic acid pharmacophore: synthesis, nitric oxide/nitroxyl release, cyclooxygenase inhibition, and anti-inflammatory studies
  作者：Zhangjian Huang、Carlos Velázquez、Khaled Abdellatif、Morshed Chowdhury、Sarthak Jain、Julie Reisz、Jenna DuMond、S. Bruce King、Edward Knaus

  DOI：10.1039/c005066k

  日期：——

  Nitric oxide (NO) and its reduced form nitroxyl (HNO), effective vasodilation agents that can inhibit platelet aggregation and adhesion, could suppress adverse cardiovascular effects associated with the use of selective COX-2 inhibitors. In this regard, a sulfohydroxamic acid (SO2NHOH) substituent, that can act as a dual NO/HNO donor moiety, was inserted at the para-position of the C2 phenyl ring of acyclic 2-alkyl-1,1,2-triaryl olefins previously shown to be potent and highly selective COX-2 inhibitors. Although this new group of 1,1-diaryl-2-(4-hydroxyaminosulfonylphenyl)alk-1-enes exhibited weak inhibition of the constitutive cyclooxygenase-1 (COX-1) and inducible COX-2 isozymes, in vivo studies showed anti-inflammatory potencies that were generally intermediate between that of the reference drugs aspirin and ibuprofen. All compounds released NO (5.6–13.5% range) upon incubation with phosphate buffer which was increased further (8.3–25.6% range) in the presence of the oxidant K3(FeCN6).The low release of HNO in MeOH-buffer (< 2% at 24 h incubation) was much higher at alkaline pH (11–37% range). The concept of designing better anti-inflammatory drugs possessing either an effective HNO, or dual NO/HNO, donor moiety that are devoid of adverse ulcerogenic and/or cardiovascular side effects warrants further investigation.

  一氧化氮（NO）及其还原形式亚硝酰氢（HNO）作为有效的血管扩张剂，能够抑制血小板聚集和粘附，可抑制与使用选择性COX-2抑制剂相关的不良心血管效应。在这方面，一种磺肟酸（SO2NHOH）取代基，可以作为双NO/HNO供体基团，被插入到先前被证明是强效且高度选择性COX-2抑制剂的非环状2-烷基-1,1,2-三芳基烯烃的C2苯环的对位。尽管这一新型1,1-二芳基-2-(4-羟胺磺酰苯基)烯烃类化合物对结构型环氧合酶-1（COX-1）和诱导型COX-2同工酶的抑制作用较弱，但体内研究显示其抗炎效力通常介于参考药物阿司匹林和布洛芬之间。所有化合物在磷酸盐缓冲液中孵育后均释放出NO（范围为5.6–13.5%），在氧化剂K3(FeCN6)存在下进一步增加（范围为8.3–25.6%）。在甲醇-缓冲液中HNO的释放量较低（孵育24小时<2%），而在碱性pH下显著升高（范围为11–37%）。设计具有高效HNO或双NO/HNO供体基团的抗炎药物，避免不良的溃疡形成和/或心血管副作用的概念值得进一步研究。
• Applying Small Molecule Microarrays and Resulting Affinity Probe Cocktails for Proteome Profiling of Mammalian Cell Lysates
  作者：Haibin Shi、Mahesh Uttamchandani、Shao Q. Yao

  DOI：10.1002/asia.201100523

  日期：2011.10.4

  present in the sample. The brightest microarray hits were converted to affinity‐based probes (AfBPs) using convenient, 1‐step “click” chemistry with benzophenone from the relevant building blocks. Pull‐down/mass spectrometric analysis with these probes (individuals or cocktail) yielded putative protein targets that include well‐known aspartic proteases, such as cathepsin D which is a clear marker for

  事实证明，小分子微阵列（SMM）越来越成为评估蛋白质与配体相互作用以及以高通量方式筛选酶底物和抑制剂的重要工具。我们之前描述了一种SMM辅助的筛选策略，用于快速鉴定针对天冬氨酸蛋白酶γ-分泌酶的探针。在本文中，我们将扩展使用羟乙基胺衍生的抑制剂的扩展库，该抑制剂非排他性地针对天冬氨酸蛋白酶。我们的库在P 2，P 1，P 1 '和P 2 '上是多样化的职位。因此，使用组合固相合成方法合成了86种新抑制剂，使总文库大小达到284种生物素化化合物，并排列在抗生物素蛋白载玻片上。为了阐明复杂生物样品中的酶活性和特性，使用荧光标记的哺乳动物细胞裂解液进行了筛选。这产生了可再现的图谱或结合指纹，与天冬氨酸蛋白酶或辅助蛋白以及样品中存在的其他相互作用靶标的相互作用相对应。最亮的芯片命中率转换为基于亲和力的探针（A fBP）使用便捷的第一步“点击”化学反应，并使用来自相关构件的二苯甲酮。使用这些探针（个人
• Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases
  申请人：——

  公开号：US20030149110A1

  公开（公告）日：2003-08-07

  The invention relates to BCAT inhibitors and the use thereof for treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the overstimulation of the excitatory amino acids, treating anxiety, psychosis, convulsions, aminoglycoside antibiotics-induced hearing loss, migraine headache, chronic pain, neuropathic pain, Parkinson's disease, diabetic retinopathy, glaucoma, CMV retinitis, urinary incontinence, opioid tolerance or withdrawal, and inducing anesthesia, as well as for enhancing cognition.

  该发明涉及BCAT抑制剂及其用于治疗或预防与中风、缺血、中枢神经系统创伤、低血糖和手术相关的神经元丧失，以及治疗包括阿尔茨海默病、肌萎缩侧索硬化、亨廷顿病和唐氏综合征在内的神经退行性疾病，治疗或预防兴奋性氨基酸过度刺激的不良后果，治疗焦虑、精神病、抽搐、氨基糖苷类抗生素引起的听力损失、偏头痛、慢性疼痛、神经痛、帕金森病、糖尿病视网膜病变、青光眼、巨细胞病毒性视网膜炎、尿失禁、阿片类药物耐受性或戒断症状，以及诱导麻醉，以及增强认知能力。

表征谱图